Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…Abstract Number: 1697 • 2018 ACR/ARHP Annual Meeting
Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?
Background/Purpose: management of systemic lupus erythematosus (SLE) patients is challenging because of the heterogeneity of the disease. While treatment of renal nephritis is more standardized,…Abstract Number: 1701 • 2018 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for…Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…Abstract Number: 2106 • 2018 ACR/ARHP Annual Meeting
Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation
Background/Purpose: Cognitive dysfunction affects up to 90% of patients with systemic lupus erythematosus (SLE), however it is grossly under-recognized, the pathogenesis is poorly understood and…Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…Abstract Number: 2652 • 2018 ACR/ARHP Annual Meeting
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
Background/Purpose: Musculoskeletal (MS) pain is a common symptom of patients with Systemic Lupus Erythematosus (SLE) affecting up to 95% of patients and contributing to…Abstract Number: 2665 • 2018 ACR/ARHP Annual Meeting
Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
Background/Purpose: Systemic lupus erythematosus (SLE) is treated with glucocorticoids, anti-malarials, immunosuppressive medications, and, more recently, biologics (specifically, belimumab and rituximab). While belimumab had positive results…Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…Abstract Number: 469 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China
Background/Purpose: Thrombotic microangiopathy (TTP) is a rare disease involving multiple organ systems. It is caused by extensive platelet thrombosis in the terminal arterioles and anterior…Abstract Number: 514 • 2017 ACR/ARHP Annual Meeting
BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
Background/Purpose: Bruton’s tyrosine kinase (BTK) is an attractive, novel therapeutic target for autoimmune disease, as it is required for signal transduction and activation via B-cell…Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting
Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…Abstract Number: 2593 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. Methods: Retrospective…Abstract Number: 2594 • 2017 ACR/ARHP Annual Meeting
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard…
- 1
- 2
- 3
- 4
- Next Page »